Neovasc Inc, a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its Tiara™ (“Tiara”) transcatheter mitral valve replacement device was featured in a presentation at the 11th Annual Transcatheter Valve Therapy Conference (“TVT 2019”). TVT 2019 is part of The Structural Heart Disease Summit held June 12-15 in Chicago, Illinois.
In a presentation titled “The TIARA Program: Attributes, Challenges, and Early Clinical Data” Dr. Anson Cheung, Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia, and Principal Investigator for the Tiara Early Feasibility Study at St Paul’s Hospital (SPH), Vancouver Canada, provided an update on the latest progress on the Tiara, including the challenging anatomical considerations, patient characteristics, procedural outcomes, and symptom improvement of patients treated with Tiara.
Read the full story on Cision News.
Story also found on Yahoo News.
